Intracellular Target of Sphingosine-1-Phosphate
1-磷酸鞘氨醇的细胞内靶标
基本信息
- 批准号:7624345
- 负责人:
- 金额:$ 3.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2007
- 资助国家:美国
- 起止时间:2007-06-18 至 2011-06-17
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAlzheimer&aposs DiseaseAnabolismApoptosisApoptoticBindingBlood VesselsBrainBrain regionBreast Cancer CellCaspaseCell Cycle ProgressionCell DeathCell NucleusCell Surface ReceptorsCell divisionCell membraneCell physiologyCellsCeramidesComplementConsensus SequenceDNADNA BindingDataDevelopmentDown-RegulationEGF geneElectrophoretic Mobility Shift AssayElementsEmbryoEngineeringEquilibriumExhibitsFamilyFibroblastsG-Protein-Coupled ReceptorsGene ExpressionGenesGenetic TranscriptionGrowthGrowth FactorHistone AcetylationHistone DeacetylaseHumanIsoenzymesKnock-outKnockout MiceLabelLentivirus VectorLipidsLocationLymphocyteMCF7 cellMammalian CellMass Spectrum AnalysisMediatingMembrane ProteinsMitosisModelingMultiple SclerosisMusNTF3 geneNerve Growth FactorsNervous system structureNeural Tube ClosureNeurodegenerative DisordersNeuroepithelialNeurogliaNeuronsNeurotrophin 3Nuclear ExtractNuclear ProteinNuclear ProteinsPC12 CellsParkinson DiseasePheochromocytomaPhosphate-Binding ProteinsPhosphotransferasesPlantsPlatelet-Derived Growth FactorPlayPolyacrylamide Gel ElectrophoresisPreventionProcessProductionProtein BindingProteinsRattusRegulationRoleSPHK1 enzymeSepharoseSmall Interfering RNASphingolipidsSphingosineSphingosine-1-Phosphate ReceptorSpinal GangliaStimulusStrokeTelencephalonVascular Endothelial Growth FactorsYeastsangiogenesisbiological adaptation to stresscell growthcell typegene repressioninterestmembrane activitymigrationnervous system disorderneuroepitheliumneurogenesisneuron lossneuronal survivalnoveloverexpressionpi bondpolyacrylamide gelsprohibitinreceptorrelating to nervous systemresponsesmall hairpin RNAsphingosine 1-phosphatesphingosine kinasesphingosine kinase type 2sphingosine-1-phosphate lyasesphingosine-1-phosphate phosphatasestress activated protein kinasetraffickingtranscription factor
项目摘要
DESCRIPTION (provided by applicant):
Sphingosine-1-phosphate (S1P) is a potent bioactive lipid that plays key roles in brain development, neuronal survival, and nervous system remodeling. Formation of SIP in neurons by sphingosine kinases (SphKs) is stimulated by a variety of agonists, including nerve growth factor (NGF) and neurotrophin-3 (NT- 3), and many of its functions are mediated by its cell surface receptors (S1P1-5). However, there is accumulating evidence suggesting that S1P also has receptor-independent intracellular effects, particularly those related to neuronal survival. A key factor hindering understanding of the intracellular roles of S1P is the lack of identification of bona fide intracellular targets. Cellular localizations of the two SphK isoenzymes that produce S1P, SphK1 and SphK2, have begun to provide some clues. SphK1 is mainly cytosolic and is activated and translocated to the plasma membrane to the vicinity of its receptors by many stimuli. In contrast, in many cell types, SphK2 is mainly found in the nucleus where its function is not known. My preliminary data indicate that S1P does bind to at least one protein that is present in the nucleus, and that it can also alter the DMA binding activity of several transcription factors. The main hypothesis of this proposal is that S1P interacts with specific intracellular targets that mediate its intracellular and/or intranuclear actions. S1P produced in the nucleus may modulate gene expression by binding to a transcription factor or to some other regulator, and the objective of this proposal is the elucidation of the direct intracellular targets of S1 P. To this end, I will identify intracellular proteins that bind S1P and investigate the effect of S1P on transcription factor DNA binding activity using a transcription factor activity membrane that allows simultaneous activity profiling of multiple transcription factors. In addition, I will determine whether intracellularly generated S1P by SphK1 or SphK2 modulates distinct transcription factor activities. Finally, the significance of the specific cellular location of S1P will be determined by altering the expression of the two sphingosine kinase isoenzymes, which are localized in different subcellular compartments. This will be accomplished by downregulation of expression of each of the kinases with small interfering RNA, and observing the effects on transcription factor activity and gene expression. Intracellular S1P enhances neuronal survival and suppresses cell death, key processes involved in neurodegenerative disorders such as stroke and Alzheimer's and Parkinson's diseases. Deciphering the mechanism of action of this sphingolipid metabolite could provide clues for the prevention and treatment of devastating human neurodegenerative diseases.
描述(由申请人提供):
1-磷酸鞘氨醇 (S1P) 是一种有效的生物活性脂质,在大脑发育、神经元存活和神经系统重塑中发挥着关键作用。神经元中鞘氨醇激酶 (SphK) 形成 SIP 受到多种激动剂的刺激,包括神经生长因子 (NGF) 和神经营养蛋白-3 (NT-3),其许多功能是由其细胞表面受体 (S1P1-5) 介导的。然而,越来越多的证据表明 S1P 还具有受体独立的细胞内效应,特别是与神经元存活相关的效应。阻碍了解 S1P 细胞内作用的一个关键因素是缺乏真正的细胞内靶标的识别。产生 S1P 的两种 SphK 同工酶(SphK1 和 SphK2)的细胞定位已开始提供一些线索。 SphK1 主要存在于细胞质中,在许多刺激下被激活并转移至质膜至其受体附近。相比之下,在许多细胞类型中,SphK2 主要存在于细胞核中,但其功能尚不清楚。我的初步数据表明,S1P 确实与细胞核中存在的至少一种蛋白质结合,并且它还可以改变几种转录因子的 DMA 结合活性。该提议的主要假设是 S1P 与介导其细胞内和/或核内作用的特定细胞内靶标相互作用。细胞核中产生的 S1P 可能通过与转录因子或其他调节因子结合来调节基因表达,本提案的目的是阐明 S1P 的直接细胞内靶标。为此,我将鉴定结合 S1P 的细胞内蛋白,并使用转录因子活性膜研究 S1P 对转录因子 DNA 结合活性的影响,该转录因子活性膜允许同时分析多个转录因子的活性。此外,我将确定 SphK1 或 SphK2 在细胞内产生的 S1P 是否调节不同的转录因子活性。最后,S1P 特定细胞位置的重要性将通过改变位于不同亚细胞区室的两种鞘氨醇激酶同工酶的表达来确定。这将通过用小干扰RNA下调每种激酶的表达并观察对转录因子活性和基因表达的影响来实现。细胞内 S1P 增强神经元存活并抑制细胞死亡,这是中风、阿尔茨海默病和帕金森病等神经退行性疾病中涉及的关键过程。破译这种鞘脂代谢物的作用机制可以为预防和治疗毁灭性的人类神经退行性疾病提供线索。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GRAHAM M STRUB其他文献
GRAHAM M STRUB的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GRAHAM M STRUB', 18)}}的其他基金
Mechanisms of microRNA-mediated regulation of cellular proliferation in vascular malformations
microRNA介导的血管畸形细胞增殖调节机制
- 批准号:
10424618 - 财政年份:2021
- 资助金额:
$ 3.44万 - 项目类别:
Mechanisms of MicroRNA-Mediated Regulation of Cellular Proliferation in Vascular Malformations
MicroRNA介导的血管畸形细胞增殖调节机制
- 批准号:
10669303 - 财政年份:2017
- 资助金额:
$ 3.44万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 3.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 3.44万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 3.44万 - 项目类别: